Case reportPublished 10 Jan 2021
Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset All
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Patients with hematologic cancers are vulnerable to infection with Severe Acute Respiratory Disease-Coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19, given their immunodeficiency due to their pathology and their chemotherapy. We present a case report of a patient with severe immunodeficiency secondary to his newly diagnosed Acute Lymphoblastic Leukemia who incidentally was found to be infected with the novel coronavirus. In an attempt to avoid serious manifestations of COVID-19, this patient was prophylactically administered COVID-19 Convalescent Plasma, an emerging treatment for COVID-19 infection. This patient was asymptomatic from his COVID-19 infection but was a high risk of developing manifestations as he was requiring immediate and intense chemotherapy. Throughout his hospital course, including his several chemotherapy treatments, this patient remained infected with SARS-CoV-2, but did not develop disease.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Oncology: Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “William R Hartman”
- BylineArticles whose byline prints “Aaron S Hess”
- BylineArticles whose byline prints “Joseph Connor”
